CVAT · 10-Q

Filing note · 10-Q · filed 2026-10-27 · Cavitation Technologies, Inc.

Cavitation Technologies, Inc. [[CVAT]]: Unlaunched $35 Million Tender Offer Amid Going-Concern Risk

### Executive Summary
Cavitation Technologies’ replacement BrightFlixx tender offer proposes $35 million in aggregate for all outstanding common shares, less company liabilities, but had not commenced and remains subject to significant closing conditions. The offer does not resolve the company’s near-term funding problem: at September 30, 2026, cash was $94,000, and management said available cash was insufficient to fund operations for the following 12 months.

### What Happened
The company’s August 14, 2026 tender agreement with European Guarantee Services was terminated in October. On October 9, Cavitation and Alchemy Beverages, in which Cavitation holds a 17% stake, entered into replacement agreements with BrightFlixx Finance Luxembourg. BrightFlixx intends to offer cash for all outstanding Cavitation common shares. The per-share price and specific liability deductions are not disclosed in filing materials; the record date is to be set 45 business days after commencement. The offer had not commenced as of the report date and is initially scheduled to remain open for 60 business days, subject to extensions.

Closing requires tenders of at least 90% of Cavitation’s outstanding shares, CFIUS approval or a no-further-action determination, and concurrent completion of BrightFlixx’s separate Alchemy offer. During the quarter, Cavitation also sold 4,666,665 shares at $0.03 per share for $140,000, issued 500,000 shares for services valued at $22,000, and issued 1,933,055 shares in a cashless warrant exercise.

### Why It Matters
The tender offer is a potential shareholder-liquidity event, not a completed transaction or a source of current operating cash. Its timing and outcome depend on the high tender threshold, regulatory clearance, and the linked Alchemy offer. Meanwhile, the company reported no quarterly revenue, $128,000 of operating cash use, and a $208,000 net loss. Its $94,000 quarter-end cash balance was supported by equity and bridge-note financing, while liabilities rose to $857,000.

The funding risk is compounded by costly financing terms and dilution: the two bridge notes carry stated interest equal to 24% of face value, with effective rates of 30.2% and 29.7%; default increases principal by 150%, and after 180 days the lender may convert at 65% of the lowest closing bid over the prior 10 trading days, subject to a 4.99% ownership limit. Separately, management deemed disclosure controls ineffective as of September 30; the cause and remediation plan are not disclosed in filing materials. Commercially, the filing describes early-stage alternatives to the declining Desmet reactor-sales opportunity, including anticipated Barmuze sales as early as the first half of fiscal 2027; that remains a projection, not established revenue.

### Context & Prior Filing Comparison
Compared with June 30, 2026, cash increased by $77,000, but liabilities rose by $119,000 and stockholders’ deficit widened by $46,000. Shares outstanding increased by approximately 7.10 million, from 317.22 million to 324.32 million. The 10-Q describes the BrightFlixx agreements as replacing the terminated EGS agreement; it does not report a commenced offer, final per-share price, or completed transaction. The 17% Alchemy interest is Cavitation’s investment in Alchemy, not an ownership stake in Cavitation.

### What to Watch Next
- Whether BrightFlixx commences the offer and sets the record date and final per-share price.
- Whether the 90% tender threshold is met, CFIUS clearance or a no-further-action determination is obtained, and the separate Alchemy offer closes concurrently.
- Cavitation’s cash needs and access to financing, given management’s stated 12-month funding shortfall.
- Bridge-note payments, default, or conversion developments; a separate $60,000 in convertible notes includes a Cavitation-share conversion option if Xyra does not achieve a public offering by December 5, 2026.

[Generated on Edgar Tracker · edgartracker.com · AI summary · GPT 6 luna · selected parts]